The cumulative lifetime risk of ovarian cancer in the general female population is estimated at 1.3%, increasing up to 36–53% and 10–25% by the age 70 in BRCA1 and BRCA2 mutation carriers, respectively [8,43,44,45], but it is basically unknown for the remaining majority of patients diagnosed with breast cancer who do not carry any pathogenetic BRCA variant. The gene discussed is BRCA1; the disease is breast cancer.